5th NovAliX Conference

Job Opening at Biogen

Explore Opportunities here

We want your opinion !

In order to further improve the quality of the meeting, we kindly ask you to take part in a short on-line survey

Follow us!

EFMC-ISMC

Spread the word with #NovAliXConference

Confirmed Speakers


Session 1: Hot Topics

OC04 - Quantitative Irreversible Tethering (QIT) for Covalent Ligand Discovery
Dr Gregory CRAVENDr Gregory CRAVEN
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Read more
OC05 - Large Protein Conformational Changes in Pi3kgamma Linked to the Binding of a New Class of Highly Selective Inhibitors
Dr Göran DAHLDr Göran DAHL
(ASTRAZENECA, Mölndal, Sweden)

Read more
OC01 - Making Off-Rate Screening in FBDD More Amenable For Fast Dissociating Compounds
Dr Menachem GUNZBURGDr Menachem GUNZBURG
(MONASH UNIVERSITY, Parkville, Australia)

Read more
OC02 - Novel Active Site and Allosteric Site Binders Identified for FPPS Of T. cruzi
Ms Joy PETRICKMs Joy PETRICK
(NOVARTIS, Basel, Switzerland)

Read more
OC03 - Dynamic Single-Molecule Approaches to Accelerate the Development of More Efficient Drugs
Dr Gerrit SITTERSDr Gerrit SITTERS
(LUMICKS, Amsterdam, The Netherlands)

Read more
IL01 - Binding Kinetics and Thermodynamics in Drug Discovery
Dr Chaohong SUNDr Chaohong SUN
(ABBVIE, North Chicago, United States)

Read more

Session 2: Target Engagement

OC06 - Quantification of Target Occupancy in Cells and Tumor Tissue Using FCCS
Dr Frank BECKERDr Frank BECKER
(INTANA BIOSCIENCE GMBH, Planegg, Germany)

Read more
IL03 - How to Be Selectively Promiscuous
Prof. Jack TAUNTONProf. Jack TAUNTON
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)
IL02 - Chemical Probes for Epigenetic Targets
Prof. Masoud VEDADIProf. Masoud VEDADI
(STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada)

Read more

Session 3: Cryo-EM (Special Feature of the Conference)

IL05 - Cryo-EM for Characterization and Structure Based Drug Design
Dr Bridget CARRAGHERDr Bridget CARRAGHER
(NEW YORK STRUCTURAL BIOLOGY CENTER, New York, United States)

Read more
IL04 - How Low Can You Go? Size and Resolution Limits Using Conventional Cryo-EM
Dr Gabriel LANDERDr Gabriel LANDER
(THE SCRIPPS RESEARCH INSTITUTE, San Diego, United States)

Read more
OC08 - Strength of Cryo-EM in Drug Discovery: One Could Always See Something
Dr Wen-ti LIUDr Wen-ti LIU
(NOVALIX, Illkirch, France)

Read more
OC07 - Cryo-EM to Address Intractable Targets in Drug Discovery
Dr Hervé REMIGYDr Hervé REMIGY
(THERMO FISHER SCIENTIFIC, Eindhoven, The Netherlands)
IL06 - Single Particle Cryo-EM Structure of the Insulin Receptor:Insulin Complex
Dr Giovanna SCAPINDr Giovanna SCAPIN
(MERCK & CO. INC (MSD), Whitehouse Station, United States)

Read more

Session 4: Membrane Proteins

IL08 - Structural Insight into Allosteric Modulation of GPCRs
Dr Miles CONGREVEDr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom)

Read more
IL07 - New Tools Reveal Mechanisms of Allosteric Coupling in Human GPCRs
Dr Matthew EDDYDr Matthew EDDY
(UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, United States)

Read more
OC10 - Crystal Structures of Human Glycine Receptor Alpha3 Bound to a Novel Class of Analgesic Potentiators
Dr Xin HUANGDr Xin HUANG
(AMGEN, Cambridge, United States)

Read more
OC09 - Enabling NMR-Based Fragment Screening Using Stabilized Native GPCR: Case Study of Adenosine Receptor
Dr Anass JAWHARIDr Anass JAWHARI
(CALIXAR, Lyon, France)

Read more

Session 5: Protein-Protein Interactions

OC11 - Use of Complementary Biophysical Methods to Characterize Ligand Binding to IL-17A
Dr Parag SAHASRABUDHEDr Parag SAHASRABUDHE
(PFIZER, Groton, United States)
OC12 - Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of α-Synuclein Aggregation in Parkinson’s Disease
Ms Roxine STAATSMs Roxine STAATS
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Read more
IL09 - Design Considerations for Synthetic Macrocycles in Drug Discovery
Prof. Adrian WHITTYProf. Adrian WHITTY
(BOSTON UNIVERSITY, Boston, United States)

Read more

Session 6: Biotherapeutics

IL13 - Emerging Higher Order Structure Techniques in Biotherapeutics Development
Dr Tapan K. DASDr Tapan K. DAS
(BRISTOL-MYERS SQUIBB, New York, United States)

Read more
IL12 - Multi-Specific Designer Proteins for Tumor Therapeutics
Dr Karyn T. O'NEILDr Karyn T. O'NEIL
(ARō BIOTHERAPEUTICS, Philadelphia, United States)

Read more
IL11 - Attacking the Cancer Cell Surface-ome with Recombinant Antibodies
Prof. Jim WELLSProf. Jim WELLS
(UCSF, San Francisco, United States)

Read more

Organised by



Sponsor

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys